Potential prior authorization for listed procedure codes

Certain CPT/HCPCS codes related to in‑vivo optical diagnostic procedures (see CPT/HCPCS section of this policy) may be subject to prior authorization. Providers should verify prior authorization requirements with the member’s plan before scheduling or billing these procedures.

• Check plan-specific code lists and bulletin for any required prior authorization.
• Examples of relevant codes include endoscopic procedures with optical endomicroscopy (e.g., 0397T) and CPT codes listed in the CPT/HCPCS section.

Prior review advised before substituting pathology

Advanced optical imaging modalities are investigational for many indications and should not be used to routinely substitute for histopathology without prior review. When clinicians propose management that bypasses standard tissue diagnosis based on in‑vivo imaging alone, prior review is advised.

• Do not forego histopathology solely on the basis of optical diagnosis unless an authorized prior review process has approved that approach.
• Document rationale and supporting evidence if proposing to substitute optical diagnosis for tissue sampling.

Prior authorization recommended for nCLE

Needle-based confocal laser endomicroscopy (nCLE) for evaluation of indeterminate pancreatic cystic lesions may require prior authorization in many plans. Prior authorization is recommended particularly for larger cysts or lesions with concerning surgical features.

• nCLE has shown promising diagnostic accuracy but carries procedure-related risks (e.g., pancreatitis); check plan rules for prior authorization and documentation requirements.
• Document indication, prior imaging/CEA/cytology results, and patient consent addressing pancreatitis risk.

Prior authorization advisable for CLE/pCLE procedures

Confocal laser endomicroscopy (CLE) and probe‑based CLE (pCLE) are novel, often costly procedures with variable evidence across indications. Consider requiring prior authorization for CLE/pCLE to ensure appropriate use and documentation.

• Confirm whether CLE/pCLE is considered investigational for the requested indication under the member’s plan.
• Require documentation of prior noninvasive testing, expected impact on management, and clinician experience with the technique.

Prior authorization not specified in this section

Some parts of this policy excerpt do not specify explicit prior authorization requirements. Where prior authorization is not specified, providers should still confirm coverage and any administrative requirements through plan resources.

• Absence of a stated prior authorization mandate in this document does not guarantee coverage — always check plan systems or bulletins.
• If no prior authorization is listed, submit complete documentation to support medical necessity at time of claim.

Prior authorization — check plan bulletin

Prior authorization requirements and administrative controls may vary by benefit plan and are described in the plan’s Clinical Policy Bulletin or member benefit documents. Providers must check the applicable bulletin or plan portal for the most current rules.

• Refer to the plan-specific Clinical Policy Bulletin Notes and review history for updates.
• When in doubt, contact plan provider services or use electronic prior authorization tools.

Experimental/Investigational — Denial risk

Procedures and indications listed in this policy as "experimental and investigational" are subject to noncoverage and denial. Submissions for these services should include robust documentation; even with documentation, denials are possible.

• Examples listed as investigational include CLE for many GI/urothelial indications, optical biopsy systems, and ERCP with optical endomicroscopy.
• If submitting for an investigational indication, include research protocols or justification for medical necessity and request prior authorization or peer‑to‑peer review when available.

Not stated in this excerpt

For some statements in the source evidence summaries, no definitive administrative action is stated. Providers should recognize where the policy or excerpt explicitly notes that an administrative requirement is "not stated" or "not specified" and seek clarification through plan channels.

• Document that the excerpt did not specify plan action when querying coverage to avoid assumptions.
• Use plan contact points to request clarification if needed.

Risk of relying on optical diagnosis in routine practice

Relying on optical in‑vivo diagnosis alone in routine community practice carries risk because accuracy reported in specialized centers may not be reproducible. Incorrect management decisions (e.g., leaving neoplastic polyps in place) can result if in‑vivo optical diagnosis is used without adequate validation, training, and documentation.

• When relying on optical diagnosis to guide management (e.g., resect-and-discard or diagnose-and-leave), document clinician training, confidence level, and the evidence basis supporting the decision.
• Consider pathology confirmation if community-practice accuracy is uncertain or if management would change substantially.

Insufficient evidence may lead to denial

The policy cites that existing evidence for many optical techniques is insufficient to establish effectiveness for routine clinical use; insufficient evidence may lead to denial when procedures are submitted as primary justification for management decisions.

• Provide comprehensive supporting evidence when requesting coverage for novel optical procedures.
• Consider prior authorization or peer review to reduce risk of claim denial.

Not explicitly stated in this section

Some background study summaries and sections do not include explicit administrative instructions. Where the policy text is silent on administrative actions, providers should treat those sections as clinical evidence summaries and follow plan processes for coverage determination.

• When the policy states "not explicitly stated," do not infer authorization — check plan systems.
• Include study-comparison elements (e.g., CLE vs histopathology) in clinical notes to support claims where applicable.

Administrative disclaimer and provider responsibility

This section contains background evidence summaries and is not itself an administrative instruction. Providers must follow plan benefit documentation and administrative rules when submitting claims or prior authorization requests.

• Use the Clinical Policy Bulletin Notes and plan portals for operational requirements.
• Treat the bulletin as guidance; the member contract governs coverage.

Documentation of high‑confidence optical diagnosis vs histopathology

When high‑confidence in‑vivo optical predictions (e.g., NBI, i‑scan OE) are used to guide management, documentation should explicitly record the confidence level, imaging criteria met, and correlation plan with histopathology or surveillance recommendations.

• Record whether the prediction was high‑confidence or low‑confidence and which validated criteria/classification system was used.
• Document recommended surveillance interval or decision to leave/resect a lesion and the rationale tied to imaging findings.

Document prediction confidence and surveillance recommendation

Clinical documentation must include the in‑vivo prediction confidence and the surveillance or management recommendation made based on that prediction, and should note whether histopathology was obtained or intentionally deferred.

• If histopathology is deferred, document justification, clinician training, and plan for follow‑up or quality assurance.
• Include correspondence with the patient about risks/benefits when management deviates from standard biopsy.

When used, documentation should include correlation with histopathology and imaging findings

When CLE or related optical modalities are used, documentation should include the specific findings, how those findings correlate with histopathology or cytology when available, and whether the imaging materially changed patient management.

• Capture operative/imaging findings, image counts, and paired histopathology locations when available.
• Include summary of how CLE findings influenced clinical decisions (e.g., altered surgical margins, avoided biopsy).

Document indication, imaging findings, correlation with prior imaging/CEA/cytology, and informed consent

For procedures such as nCLE, document the indication, lesion characteristics, imaging findings, prior relevant testing (CEA, cytology, imaging), informed consent (including risk of pancreatitis), and comparison with reference standards.

• Record size and imaging appearance of pancreatic cystic lesions, prior EUS/CT findings, and CEA/cytology results.
• Document patient counseling about pancreatitis risk and post‑procedure monitoring plan.

Studies compared CLE-based diagnoses to standard histopathology/cytology

Studies of CLE often compared CLE-based diagnoses to standard histopathology or cytology and reported agreement metrics. When billing or requesting prior authorization for CLE, include study-comparison methods and relevant outcome measures if applicable to clinical decision-making.

• Where available, append or reference paired histology comparisons, sensitivity/specificity, and study identifiers to support clinical justification.
• Note whether local results mirror published performance.

Image‑histology pairing and blinded classification documented in studies

Clinical studies frequently documented image-to-histology pairing and used blinded classification or independent reviewers. When CLE is used, include these methodological elements in documentation when possible to strengthen the evidentiary record.

• Record number of images, methods of pairing images to biopsy sites, and whether blinded review or independent raters were used.
• Include inter- and intra-observer agreement statistics when available.

Study documentation elements to include when applicable

Research studies using CLE reported specific documentation elements such as number of images, concordance with histopathology/cytopathology, blinded rater methods, and diagnostic accuracy metrics. Incorporate these elements into clinical records when applicable.

• Document number of CLE sequences/images acquired and evaluable rate.
• Include concordance metrics and any validated scoring systems applied (e.g., Miami, Paris, DOC score).

Provider responsibility — follow plan documentation and bulletin

Providers are responsible for following plan benefit documentation requirements and the Clinical Policy Bulletin. Treat the bulletin as a guide; ultimate coverage determinations are subject to the member contract and plan administrative processes.

• Ensure clinical documentation supports the requested service and aligns with plan procedures for prior authorization and appeals.
• Contact plan provider services for operational questions.

Implementation caution for chromoendoscopy

Implementation of chromoendoscopy in some real‑world settings did not improve dysplasia detection versus white‑light endoscopy with targeted and random biopsies in important studies. Exercise caution before changing surveillance protocols or abandoning standard tissue sampling based solely on chromoendoscopy.

• If proposing chromoendoscopy-based changes to surveillance practice, include evidence and local performance data.
• Do not replace standard random or targeted biopsies without validated local outcomes and plan approval.

Step‑therapy and utilization limits not specified

This section does not specify step‑therapy protocols or quantity limits. No step‑therapy requirements are described in the policy excerpts provided; verify plan-specific utilization management policies if relevant.

• If a plan imposes step therapy or staging for advanced optical procedures, that information will be in the plan bulletin or prior authorization guidance.
• When absent, provide full clinical rationale and prior testing to support requests.